{"id":"W4412488898","doi":"10.1182/bloodadvances.2024014654","title":"Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti–PD-1–refractory Hodgkin lymphoma","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"National Cancer Institute","keywords":"Pembrolizumab; Medicine; Refractory (planetary science); Internal medicine; Clinical trial; Lesion; Oncology; Gastroenterology; Surgery; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001225466,0.0003441402,0.0008789354,0.0004548169,0.00009337469,0.00002122703,0.0001813127,0.0001223347,0.00003415424],"category_scores_gemma":[0.0005556681,0.0002928078,0.0001832823,0.0007651675,0.0001019163,0.0002650011,0.0001213774,0.0001154024,0.00003281368],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000391005,"about_ca_system_score_gemma":0.0004901673,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002130375,"about_ca_topic_score_gemma":0.0000529767,"domain_scores_codex":[0.9978252,0.00007866648,0.0006863309,0.0005883045,0.0003696542,0.0004518501],"domain_scores_gemma":[0.9984704,0.0005408164,0.0002223272,0.0004844413,0.0001308132,0.0001512171],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.006052122,0.01536216,0.478671,0.001702772,0.001531549,0.001357584,0.004666514,0.006388765,0.006627612,0.008970662,0.0005642811,0.4681049],"study_design_scores_gemma":[0.04431865,0.00124481,0.9225674,0.002468609,0.0005756323,0.00007543817,0.0003057833,0.0007694991,0.02259991,0.0005304389,0.004167174,0.0003767041],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9777762,0.007368972,0.000235806,0.0005145074,0.0003056089,0.0009264036,0.00002398316,0.00008430117,0.01276418],"genre_scores_gemma":[0.9896017,0.0002804273,0.00917139,0.0002804016,0.00008115914,0.0001380506,0.00002397533,0.0000282406,0.0003946457],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4677282,"threshold_uncertainty_score":0.9999524,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01017227258864854,"score_gpt":0.3021202913284249,"score_spread":0.2919480187397763,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}